FDA — authorised 23 January 2020
- Application: NDA211723
- Marketing authorisation holder: EPIZYME INC
- Local brand name: TAZVERIK
- Indication: TABLET — ORAL
- Status: approved
🇺🇸 Tazverik in United States
FDA authorised Tazverik on 23 January 2020
Marketing authorisation
Tazverik in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Tazverik approved in United States?
Yes. FDA authorised it on 23 January 2020.
Who is the marketing authorisation holder for Tazverik in United States?
EPIZYME INC holds the US marketing authorisation.